In May 2025, Illumina, Inc., and Ovation.io, Inc., announced the development of the largest commercially available clinical multiomic dataset from 25,000 patients treated with glucagon-like peptide-1 (GLP-1) receptor agonist therapies
(3) Clemmons DR
Patients who want a straightforward, nightly injection protocol and have goals like gradual fat loss, improved recovery, better sleep and vitality may consider Sermorelin
As a GHRH secretagogue that is subcutaneously injected, ipamorelin likely causes side effects related to frequent injections such as pain, rash or soreness at injection sites, in common with other forms of GH therapies [19]
In most comparisons, yes
Serious adverse effects are rare at prescribed doses